D. Boral Capital Reaffirms Buy Rating for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating restated by D. Boral Capital in a research report issued on Friday,Benzinga reports. They currently have a $10.00 price objective on the medical research company’s stock.

A number of other analysts have also recently weighed in on CTSO. HC Wainwright restated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. StockNews.com began coverage on shares of Cytosorbents in a research note on Saturday, December 28th. They issued a “hold” rating for the company. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Trading Up 1.8 %

Shares of NASDAQ CTSO opened at $0.94 on Friday. The business has a fifty day moving average price of $0.92 and a 200 day moving average price of $1.02. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.59. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The stock has a market capitalization of $51.21 million, a P/E ratio of -2.60 and a beta of 0.58.

Institutional Investors Weigh In On Cytosorbents

A number of large investors have recently modified their holdings of CTSO. Sargent Investment Group LLC boosted its stake in Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after purchasing an additional 192,747 shares in the last quarter. Atomi Financial Group Inc. acquired a new stake in shares of Cytosorbents during the third quarter worth $51,000. Finally, Geode Capital Management LLC lifted its stake in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.